

## Atezolizumab IMpassion130

## PRELIMINARY SCORE

### CURATIVE




### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



## Atezolizumab IMpassion130

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Therapeutic Indication: Treatment of patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression  $\geq 1\%$  and who have not received prior ChT for metastatic disease  
Experimental Arm: Atezolizumab + Nab-paclitaxel  
Control Arm: Placebo + nab-paclitaxel

